Ascendiant analyst Lucas Ward initiated coverage of 60 Degrees Pharmaceuticals with a Buy rating and $2.40 price target. The company’s FDA-approved Malaria prophylactic has shown promise against new indications including COVID, providing a “powerful catalyst for stock value over the medium term,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SXTP:
- 60 Degrees Pharmaceuticals withdraws ACLR8-LR IND application
- 60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements
- 60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference
- 60 Degrees Pharmaceuticals study published in ‘New Microbes and New Infections’
- 60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity